Mirum Pharmaceuticals, Inc.
MIRM
Pozycja w akcjach
#3274
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Cena akcji
$82.58
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$5.36B
Zmiana (1 dzień)
3.05%
Zmiana (1 rok)
13.08%
Kraj
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategoria
Healthcare
Wskaźnik P/S dla Mirum Pharmaceuticals, Inc. (MIRM)
Wskaźnik P/S na dzień October 2026 TTM: 8.40
Według najnowszych raportów finansowych i ceny akcji Mirum Pharmaceuticals, Inc., obecny wskaźnik P/S (TTM) wynosi 8.40. Na koniec 2023 wynosił 6.48.
Historia wskaźnika P/S dla Mirum Pharmaceuticals, Inc. od 2018 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 8.40 | 44.09% |
| 2024 | 5.83 | -9.93% |
| 2023 | 6.48 | -24.37% |
| 2022 | 8.56 | -66.12% |
| 2021 | 25.27 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 10.02 | 19.31% |
US
|
|
| 40.55 | 382.73% |
US
|
|
| 3.96 | -52.85% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 20.78% |
NL
|
